Madrigal Pharmaceuticals, Inc. develops and commercializes therapies for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease that can progress to cirrhosis and liver failure. Its principal medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist approved by the FDA and European Commission for MASH with moderate to advanced fibrosis.
Company news regularly covers Rezdiffra sales and patient adoption, quarterly financial results, regulatory and clinical development updates, and pipeline expansion through licensed assets such as ARO-PNPLA3, a clinical-stage siRNA program targeting PNPLA3, and an oral GLP-1 receptor agonist program. Madrigal also issues recurring corporate-governance updates, including Nasdaq inducement awards under its employee equity plans.
Madrigal Pharmaceuticals (NASDAQ:MDGL) granted inducement equity awards on March 1, 2026 to 20 new non-executive employees under its 2025 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The awards total options to purchase 789 shares and 6,882 RSUs, with options priced at $432.00 (closing price on grant date) and time‑based vesting over four years subject to continued employment.
Madrigal Pharmaceuticals (Nasdaq: MDGL) will participate in the TD Cowen 46th Annual Health Care Conference on March 3, 2026 at 2:30 P.M. ET. The presentation will be webcast live and can be accessed via the company’s Investor Relations Events page. A replay will be available after the event.
Madrigal Pharmaceuticals (NASDAQ: MDGL) reported fourth-quarter and full-year 2025 net sales of $321.1M and $958.4M, respectively, with more than 36,250 patients on Rezdiffra as of year-end 2025. Cash and marketable securities totaled $988.6M at Dec. 31, 2025.
Key 2025 developments include Orange Book patent protection into 2045, EU launch in Germany, a $350M initial term loan within a $500M credit facility, licensing deals for siRNA programs and oral GLP-1 (MGL-2086), and a Phase 2 DGAT-2 license for ervogastat.
Madrigal Pharmaceuticals (NASDAQ:MDGL) granted equity inducement awards on Feb 15, 2026 to five new non-executive employees under its 2025 Inducement Plan, approved by the independent Compensation Committee under Nasdaq Listing Rule 5635(c)(4).
The awards total 2,749 time-based restricted stock units that vest in four equal annual installments on each of the first through fourth anniversaries of the grant date, subject to continued employment on each vesting date.
Madrigal Pharmaceuticals (NASDAQ: MDGL) secured an exclusive worldwide license from Ribo and Ribocure for six pre-clinical siRNA programs targeting metabolic dysfunction-associated steatohepatitis (MASH).
Terms include a US$60M upfront, potential cumulative payments up to US$4.4B for milestones, and royalties on net sales. The deal uses Ribo's GalSTAR™ liver-targeting siRNA platform with options to expand into bi-specific siRNAs.
Madrigal (NASDAQ: MDGL) signed an exclusive global license with Ribo for six preclinical siRNA programs to expand its MASH pipeline, which now exceeds 10 programs and is anchored by Rezdiffra.
Key terms include a $60 million upfront payment, up to $4.4 billion in program milestones, royalties on net sales, and IND-enabling activities beginning in 2026.
Madrigal Pharmaceuticals (NASDAQ:MDGL) granted inducement equity awards on February 1, 2026 to 21 new non-executive employees under its 2025 Inducement Plan.
The company issued an aggregate of 5,861 time-based restricted stock units that vest in four equal annual installments, subject to continued employment and Compensation Committee approval under Nasdaq Rule 5635(c)(4).
Madrigal Pharmaceuticals (Nasdaq: MDGL) will release its fourth-quarter and full-year 2025 financial results on Thursday, Feb. 19, 2026, before the U.S. market open. A live webcast with management will follow at 8:00 a.m. Eastern Time and will be posted on the company’s Investor Relations website approximately two hours later. Participants are advised to register at least 15 minutes before the webcast for a timely connection.
Madrigal Pharmaceuticals (NASDAQ:MDGL) announced on January 22, 2026 that it granted inducement equity awards on January 15, 2026 to 40 new non‑executive employees under its 2025 Inducement Plan and in accordance with Nasdaq Listing Rule 5635(c)(4).
The grants total options to purchase 3,049 shares and 13,145 time‑based restricted stock units (RSUs). Options carry an exercise price of $495.88, equal to the closing price on the grant date. Option vesting: 25% on the first anniversary, then 6.25% each quarterly anniversary thereafter. RSUs vest in four equal annual installments on the first through fourth anniversaries. All vesting is subject to continued employment as of each vesting date.
Madrigal Pharmaceuticals (NASDAQ:MDGL) granted an inducement equity award on Jan 15, 2026 to Rita Thakkar upon her hiring as Chief Accounting Officer. The award, approved under Nasdaq Listing Rule 5635(c)(4), comprises 2,398 time-based restricted stock units and options to purchase 1,826 shares with an exercise price of $495.88 per share (equal to the closing price on the grant date). Options vest 25% after one year and 6.25% each quarter thereafter; RSUs vest in four equal annual installments. All vesting is conditioned on continued employment as of each vesting date.